Events | Incidences | Subtypes | P** | |||||||
---|---|---|---|---|---|---|---|---|---|---|
TNBC is defined as ER/PR positive staining in <1% cells | ||||||||||
Alla (n = 157) | HR+/HER2− (ER/PR ≥1%) (n = 75) | HER2+ (n = 46) | TN (ER/PR <1%) (n = 36) | P | ||||||
LRR | 12b | (7.6%) | 4 | (5.3%) (p = 0.037)π | 1 | (2.2%) (p = 0.019)π | 7 | (19.4%) | 0.014 | |
DM | 22 | (14.0%) | 11 | (14.7%) (p = 0.78)π | 5 | (10.9%) (p = 0.52)π | 6 | (16.7%) | 0.73 | |
Death | 21 | (13.4%) | 8 | (10.7%) (p = 1.0)π | 7 | (15.2%) (p = 0.75)π | 4 | (11.1%) | 0.77 | |
Non-pCR (n = 132) | HR+/HER2− (ER/PR ≥1%) (n = 71) | HER2+ (n = 34) | TN (ER/PR <1%) (n = 27) | P | ||||||
LRR | 11 | (8.3%) | 4 | (5.6%) (p = 0.025)π | 1 | (3.0%) (p = 0.037)π | 6 | (22.2%) | 0.023 | |
DM | 21 | (15.9%) | 11 | (15.5%) (p = 0.76)π | 5 | (14.7%) (p = 0.74)π | 5 | (18.5%) | 0.90 | |
Death | 19 | (14.4%) | 8 | (11.3%) (p = 0.73)π | 7 | (20.6%) (p = 0.74)π | 4 | (14.8%) | 0.40 | |
TNBC is defined as ER/PR positive staining in <10% cells | ||||||||||
Alla (n = 157) | HR+/HER2− (ER/PR ≥10%) (n = 68) | HER2+ (n = 46) | TN (ER/PR <10%) (n = 43) | P | ||||||
LRR | 12b | (7.6%) | 2 | (2.9%) (p = 0.003)π | 1 | (2.2%) (p = 0.006)π | 9 | (20.9%) | 0.001 | |
DM | 22 | (14.0%) | 9 | (13.2%) (p = 0.59)π | 5 | (10.9%) (p = 0.37)π | 8 | (18.6%) | 0.59 | |
Death | 21 | (13.4%) | 5 | (7.3%) (p = 0.21)π | 7 | (15.2%) (p = 1.0)π | 7 | (16.3%) | 0.27 | |
Non-pCR (n = 132) | HR+/HER2− (ER/PR ≥10%) (n = 64) | HER2+ (n = 34) | TN (ER/PR< 10%) (n = 34) | P | ||||||
LRR | 11 | (8.3%) | 2 | (3.3%) (p = 0.003)π | 1 | (2.9%) (p = 0.027)π | 8 | (23.5%) | 0.002 | |
DM | 21 | (15.9%) | 9 | (14.8%) (p = 0.41)π | 5 | (14.7%) (p = 0.75)π | 7 | (20.6%) | 0.68 | |
Death | 19 | (14.4%) | 5 | (7.8%) (p = 0.10)π | 7 | (20.6%) (p = 1.0)π | 7 | (20.6%) | 0.11 |